NCT06507475Completed
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
Real World Effectiveness of Oral Semaglutide in Thailand Patients With Type 2 Diabetes: an Observational, Multicentre, Retrospective Cohort Study REAL-world Effectiveness of Oral Semaglutide In a Cohort of Thai patientS With Type 2 Diabetes treatED With Oral Antidiabetic Medications (REALISED) Study
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 209 (actual)
- First submitted
- 12 Jul 2024
- Start date
- 7 Sept 2024
- Primary completion date
- 20 Dec 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Type 2 diabetes
- NCT number
- NCT06507475
What you commit to
- Study type: Observational
- Participants enrolled: 209
- From 7 Sept 2024 to the primary completion date, 20 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in this study. Participation is defined as having given informed consent in this study (if applicable).
Other illness
- Participants with any diagnosis of type 1 diabetes (T1D).
Lab values
- Medical records documenting prior or ongoing treatment with injectable glucose-lowering treatment.
Who the study is looking for
- Adult Thai male or female patients aged greater than or equal to (≥) 18 years.
- Diagnosed with T2D either through International Classification of Diseases (ICD) code or by physician's description such as documentation in the medical record, and who have not previously been treated with injectable glucose-lowering medication.
- At least one recent or closest Glycated Haemoglobin (HbA1c) test value available and documented less than or equal to 12 weeks prior to the initiation of oral semaglutide.
- Had initiated oral semaglutide for diabetes during the target selection period of April 2022 to December 2023. All required data for collection should already be accessible prior to the initiation of data collection.
- Treated with oral semaglutide for at least 6 months without interruption or discontinuation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Maharaj Nakorn Chiang Mai Hospital_Nephrology Coordinator of this site? Confirm its status | Chiang Mai | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.